// App-Quantinova.ai

TPS8581 : EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).

Researchers

Presenter

  • Jamie E. Chaft

Principal Investigators

  • Suzanne Eleanor Dahlberg

  • Onkar V Khullar

  • Martin J. Edelman

  • Charles B. Simone

  • John Heymach

  • Charles M. Rudin

  • Suresh S. Ramalingam

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Dana-Farber Cancer Institute, Boston, MA

  • Emory University School of Medicine, Atlanta, GA

  • Fox Chase Cancer Center, Philadelphia, PA

  • University of Maryland, Baltimore, MD

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Winship Cancer Institute of Emory University, Atlanta, GA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Crizotinib

  • Erlotinib hydrochloride

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02194738

  • NCT02193282

  • NCT02201992

  • NCT02595944

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved